Cardiovascular side effects in patients treated with some selected antipsychotics. Preliminary results
Keywords:
atypical antipsychotics, ecg, QT intervalAbstract
Introduction: Treatment with antipsychotics is associated with cardiovascular side effects. This results from mechanism of action of antipsychotic agents because these drugs are affinity antagonist at adrenergic histamine, cholinergic and serotonine receptors. Arrhythmias are the serious side effects. Treatment with antipsychotics may prolong QTc and increase the risk of dangerous supraventricular and ventricular arrhythmias.
Objectives: The main aims of the research are the following: If any antipsychotics agents may prolong QT interval? If treatment with olanzapine, ziprasidone and aripiprazole may induce any arrhythmias? Methods: Data for this study were collected from 51 patients hospitalized in the Department of Adult Psychiatry and treated with olanzapine (n=20), aripiprazole (n =16), ziprasidone (n=15). All patients had 12 leads ECG two times: before admitting the drugs and during the treatment. All ECG were assessed on the presence of any abnormalities and QTc was calculated manually by using Bazzet formula.
Results: Among treated patients no significant QTc prolongation was observed. There was no prolonged QTc over 450ms in Male and 470 ms in female patients treated with antipsychotics. Potassium level in all patients was within the norm. Bradykardia (< 50/min) and tachykardia (>100/min) was not observed among participants.
Conclusions: Atypical antipsychotics such as olanzapine, aripiprazole, ziprasidone are cardiovascular safe drugs. They did not induce dangerous for life arrhythmias especially ventricular arrhythmia (known as torsades de pointes), which can progress to ventricular fibrillation and sudden death.
References
1. Mackin P. Cardiac side effects of psychiatric drug in human psychopharmacology: Clinical and Experimental, 2008; 23: 3-14.
2. Hedley P.L., Jorgensen P., Schlamowitz S., Wangari R., Moolman – Smook J., Brink P.A., Kanters J.K., Corfield V.A., Chrostiansen M. The genetic basis of long QT and short QT syndromes: a mutation update. Hum. Mutat., 2009; 30(11): 1486-1511.
3. Haddad P.M., Anderson I.M. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs, 2002; 62:1649-1671.
4. Gupta A., Lawrence A.T., Krishan K., Kavinsky C.J., Trohman R.G. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am. Heart. J., 2007; 153: 891-899.
5. Bazzet H.C. An analysis of the time relations of electrocardiogram. Heart, 1920; 7: 353.
6. Hodges M., Salerno D., Erlien D. Bazett’s QT correlation reviewed. Evidence that a linear QT correction for heart is better. J. Amer. Coll. Cardiol., 1983; 1: 694.
7. Bednar M.M., Harrigan E.P., Anziano R.J., Camm A.J., Ruskin J.N. The QT interwal. Prog Cardiovasc Dis, 2001; 43(5 Suppl 1): 1-45.
8. Strachan E.M., Kelley C.A., Bateman D.M. Electrocardiogram and cardiovascular changes in thioridazine and chlorpromazine poisoning. Eur. J. Clin. Pharmacol., 2004; 60: 541-545.
9. Choi S.Y., Koh Y.S., Jo S.H. Inhibition of human ether-a-go-gorelated gene K+ channel and IKr of guinea pig cardiomyocytes by antipsychotic drug trifluoperazine. J. Pharmacol. Exp. Ther., 2005; 313: 888-895.
10. Glassman A.H., Bigger J.T. Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am. J. Psychiatry, 2001; 158: 1774-1782.
11. Yap Y.G., Camm A.J. Drug induced QT prolongation and torsad es de pointes. Heart, 2003; 89: 1363-1372.
12. Reilly J.G., Ayis S.A., Ferrier I.N., Jones S.J., Thomas S.H. QTcinterval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet, 2000; 355(9209):1048-1052.
13. Czekalla J., Beasley C.M. Jr, Dellva M.A., Berg P.H., Grundy S. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J. Clin. Psychiatry, 2001; 62: 191-198.
14. Kane J.M., Carson W.H., Saha A.R., McQuade R.D., Ingenito G.G., Zimbroff D.L., Ali M.W. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry, 2002; 63(9): 763-771.
15. Marder S.R., McQuade R.D., Stock E., Kaplita S., Marcus R., Safferman A.Z., Saha A., Ali M., Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo- controlled trials. Schizophr. Res., 2003; 61(2-3):123-136.
16. Kelly D.L., Love R.C. Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations. Psychopharmacol. Bull., 2001; 35: 66.79.
17. Biswas A.K., Zabrocki L.A., Mayes K.L., Morris-Kukoski C.L. Cardiotoxicity associated with intentional ziprasidone and bupropion overdose. J. Toxicol. Clin. Toxicol., 2003; 41: 79-82.
18. Miceli J.J., Anziano M.S., Swift R.H., et al. IM ziprasidone and IM haloperidol show comparable QTc effects at Cmax. Poster presented at: 156th Annual Meeting of the American Psychiatric Assciation; May 17-22, 2003; San Francisco, CA.
19. Miceli J.J., Murray S., Sallee F.R., Tensfeldt T.G., Versavel M. Phamacokinetic and pharmacodynamic QTc profile of oral ziprasidone in pediatric and adult subjects following single-dose administration. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
Downloads
Published
Issue
Section
License
Copyright (c) 2011 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
